Login/Register
Getmeds, a trusted provider of affordable cancer, hematology, and anesthesia products, is taking a meaningful step forward by offering the most cost-effective teriparatide injection pen biosimilar in the Philippine market. This initiative provides an accessible treatment option for patients affected by osteoporosis and other serious bone-related conditions.
The innovative injection pen have been carefully designed for the convenience and ease of use of patients with osteoporosis. Key features include:
- Side injection button for effortless dosing
- Integrated dose counter for precise tracking
- No priming required — ready to use immediately
- Pre-filled pen — no need to replace drug cartridges (pen is single-use and not reusable)
- 360-degree transparent view of the drug solution
- Stable at room temperature — no refrigeration needed
Teriparatide is a synthetic form of parathyroid hormone that stimulates new bone growth. It is widely recommended for postmenopausal women, men with primary osteoporosis, and individuals with glucocorticoid-induced osteoporosis who are at high risk of fractures.
The product is a 20 μg/80 μL solution for injection, presented in a pre-filled pen. Each daily dose delivers 20 μg of teriparatide in 80 μL, administered subcutaneously in the thigh or abdomen. Each teriparatide pen dosage contains 2.4 mL of solution, equivalent to 600 μg of teriparatide (250 μg/mL), and is packaged one pen per box.
This affordable biosimilar offers comparable safety, efficacy, and quality to the original drug—delivered at a significantly lower cost to ensure wider access to this life-changing therapy. Please note that teriparatide biosimilar is a prescription medicine and should only be used under the supervision and guidance of a licensed healthcare professional.
“After successfully introducing the most affordable sugammadex anesthesia in the Philippines, we are now bringing the same unwavering commitment to accessibility and quality healthcare with the country’s first affordable teriparatide biosimilar,” said Director Naresh Bishnoi of Getmeds. “This milestone marks another step forward in providing Filipino patients and healthcare providers with innovative, cost-effective treatment options that improve outcomes and enhance lives.”
Getmeds, as the provider of this first affordable teriparatide biosimilar, is committed to working closely with healthcare providers, doctors, hospitals, and pharmacies to ensure nationwide availability. By offering teriparatide injection at a price point that prioritizes patient access and equity, Getmeds aims to support better treatment adherence and improved patient outcomes across the healthcare system.
Disclaimer
This blog is intended for licensed healthcare professionals in the Philippines only.
The information provided is for educational and informational purposes regarding an upcoming prescription product. This is not a substitute for professional medical advice.
By clicking the inquiry button, you confirm that you are a licensed HCP authorized to request product information
Getmeds
Email: info@getmeds.ph
Phone: 09190769105
Be the first to comment on "First Affordable Teriparatide Injection Biosimilar Will Enter the Philippine Market — A Future of Cost-effective Bone Health Treatment"